Skip to main content
. Author manuscript; available in PMC: 2012 Jun 26.
Published in final edited form as: Mol Cell. 2011 Jun 24;42(6):731–743. doi: 10.1016/j.molcel.2011.04.024

Figure 6. Thapsigargin does not block endocytosis-mediated EGFR degradation.

Figure 6

(A) MEFs were treated as described in the methods section for the EGF receptor degradation assay. Post EGF addition, cells were chased in cycloheximide, with/without 3 μM thapsigargin, or 10 nM bafilomycin A1. (B) Quantitation of EGFR degradation. Values represent mean percentage decrease in EGF receptor levels ± SD from three independent experiments. (C) MEFs were incubated in complete media (control) or complete media with 3 μM thapsigargin for 5 h (thapsigargin). Following 2 h of thapsigargin treatment, 5 mg/ml FITC-dextran (green) was added for a further 2.5 h and then cells were washed and incubated in complete media containing 100 nM Lysotracker (red) with/without thapsigargin for the final 30 min. Cells were stained with DAPI (blue). Bar, 10 μm. (D) Quantitation of data represented in (C). Values represent mean number of dextran structures per cell that were positive for lysotracker stain ± SD, from two independent experiments and a total of 20 cells. See also Figure S4.